Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea

NCT05144945 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

301

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza (Healthy Volunteers)

Interventions

BIOLOGICAL: Quadrivalent Recombinant Influenza Vaccine (RIV4)
BIOLOGICAL: Quadrivalent inactivated influenza vaccine (IIV4)

Sponsor

Sanofi Pasteur, a Sanofi Company